HanaVax
HanaVax Inc. is dedicated to developing nasal vaccines as a new solution for global health, focusing on mucosal vaccine technology to combat infectious diseases.
Industries
Nr. of Employees
small (1-50)
HanaVax
3-1-1 Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
Patents
Products
Rice-based oral vaccine candidate (edible powdered rice platform)
Edible powdered rice formulation designed as an oral vaccine candidate for enteric pathogens; reported to have completed Phase I human safety evaluation.
Trivalent protein-based pneumococcal nasal vaccine candidate (nanogel delivery)
Protein antigen formulation delivered via an adjuvant-free nanogel intranasal delivery system; reported protective efficacy in non-human primate challenge studies.
Rice-based oral vaccine candidate (edible powdered rice platform)
Edible powdered rice formulation designed as an oral vaccine candidate for enteric pathogens; reported to have completed Phase I human safety evaluation.
Trivalent protein-based pneumococcal nasal vaccine candidate (nanogel delivery)
Protein antigen formulation delivered via an adjuvant-free nanogel intranasal delivery system; reported protective efficacy in non-human primate challenge studies.
Services
Research and development of nasal and oral vaccine candidates for infectious diseases, covering formulation, preclinical testing, and support toward early clinical evaluation.
Research and development of nasal and oral vaccine candidates for infectious diseases, covering formulation, preclinical testing, and support toward early clinical evaluation.
Expertise Areas
- Mucosal vaccine development
- Intranasal vaccine delivery
- Oral/edible vaccine platforms
- Nanogel delivery systems
Key Technologies
- Nanogel-based mucosal delivery
- Cationic nanogel formulations
- Rice-based edible vaccine platform
- Intranasal vaccine formulation
News & Updates
Research publication on rice-based oral vaccine MucoRice.
Partnership for COVID-19 vaccine development using nanogel technology.
Media coverage of MucoRice in Ruptly.
Research publication on nasal vaccines by scientific advisor Dr. Nakahashi.
Research on a nanogel-based nasal vaccine showing protection in macaques.
Study on vaccine formulation using nanogel delivery system.
Research publication on rice-based oral vaccine MucoRice.
Partnership for COVID-19 vaccine development using nanogel technology.
Media coverage of MucoRice in Ruptly.
Research publication on nasal vaccines by scientific advisor Dr. Nakahashi.
Research on a nanogel-based nasal vaccine showing protection in macaques.
Study on vaccine formulation using nanogel delivery system.